MacroGenics

MacroGenics Employees

The The number of employees of MacroGenics (MGNX) as of Nov 20, 2026 is 293. In the previous year, The number of employees was 293.00 — a change of 0.00% (lower).

Employees

293

YoY

0.00%

Last updated:

In 2025, MacroGenics employed 293 people, a 0.00% change from the 293.00 number of employees in the previous year.

The MacroGenics Employees history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Employees
Date
Employees
Jan 1, 2018
293.00 USD
Jan 1, 2019
293.00 USD
Jan 1, 2020
293.00 USD
Jan 1, 2021
293.00 USD
Jan 1, 2022
293.00 USD
Jan 1, 2023
293.00 USD
Jan 1, 2024
293.00 USD
Jan 1, 2025
293.00 USD
The MacroGenics Employees history
YEAREmployeesYoY
2930.00%
2930.00%
2930.00%
2930.00%
2930.00%
2930.00%
2930.00%
2930.00%
2930.00%
2930.00%
2930.00%
293—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MacroGenics Stock analysis

What does MacroGenics do? MacroGenics Inc is a biotechnology company that was founded in 2000 and is headquartered in Rockville, Maryland, USA. The company specializes in the research, development, and commercialization of therapeutic antibodies used in the treatment of cancer and autoimmune diseases. MacroGenics' business model is based on the production of different antibodies that primarily target various cell types and thereby elicit a targeted response. The company relies on a balanced approach to research and development to preferentially identify cellular markers that are characteristic of certain diseases, allowing for the identification of specific target molecules for antibody development. These innovative therapies lead to an improvement in the quality of life for patients by curing or at least managing severe diseases. Over the years, MacroGenics has built several divisions, including: Antibody platform technologies MacroGenics utilizes its proprietary platform technology for phage display and antibody manufacturing (Digitalis), as well as for the discovery of target molecules responsible for specific diseases. These technologies are used to identify new therapeutic antibody candidates and support the entire antibody development process. Cancer research and development MacroGenics is a pioneer in the development of innovative cancer therapies. One of the key products in this area is the antibody-based cancer drug Margetuximab, used for the treatment of metastatic breast cancer. Another promising drug in clinical phases is MGD019, which is highly effective for tumor treatment in the solid area. Autoimmune research and development MacroGenics is a leading developer of Neuromyelitis Optica Spectrum Disorder (NMOSD), which leads to recurring inflammation of the central nervous system. Additional products in the pipeline are being developed for the treatment of autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, as there is still a wide range of needs in this field. Polyclonals and biosimilars This area includes the production of antibody polypeptides and biosimilar drugs. Antibody polypeptides can be used to treat infectious diseases or diagnose diseases. Biosimilar drugs are biological drugs that have similar active ingredients to other already approved drugs and are approved by the US Food and Drug Administration (FDA). These drugs are also known as generic replicas. MacroGenics' products have proven to be safe and effective in clinical trials. The company has established an extensive network of collaborations to market and distribute its products. Partners include major pharmaceutical companies such as Pfizer, Servier, and Janssen Biotech. Overall, MacroGenics has over 20 product pipelines in various stages of development and is constantly working to expand its product pipelines. The company employs over 400 employees and aims to revolutionize the treatment of severe and life-threatening diseases. In conclusion, MacroGenics Inc is an innovative biotechnology company that has developed and designed a variety of products for the treatment of cancer and autoimmune diseases. The company has a wide range of proprietary platform technologies and is constantly striving to expand its product pipelines. We expect the company to continue growing in the coming years and harness its innovative power to further benefit patients. MacroGenics is one of the most popular companies on Eulerpool.

Employees Details

Examining MacroGenics's Employee Base

MacroGenics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding MacroGenics's operational capacity and future potential.

Year-to-Year Comparison

Assessing MacroGenics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

MacroGenics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in MacroGenics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about MacroGenics stock

The number of employees of MacroGenics is 293 in 2025.

The number of employees of MacroGenics changed from 293.00 to 293, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of employees MacroGenics since 2006 – with annual values, charts, and detailed analysis.

The number of employees describes the number of people directly employed by the company.

The number of employees's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The number of employees's MacroGenics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — MacroGenics

All Key Metrics — MacroGenics